

Exploring Developments in IgAN and FSGS

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [published online ahead of print, 2023 Nov 2]. *Lancet*. 2023;S0140-6736(23)02302-4. doi:10.1016/S0140-6736(23)02302-4

<https://pubmed.ncbi.nlm.nih.gov/37931634/>

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X

<https://pubmed.ncbi.nlm.nih.gov/37015244/>

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial [published correction appears in *Lancet*. 2023 Sep 9;402(10405):850]. *Lancet*. 2023;402(10405):859-870. doi:10.1016/S0140-6736(23)01554-4

<https://pubmed.ncbi.nlm.nih.gov/37591292/>

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis [published online ahead of print, 2023 Nov 3]. *N Engl J Med*. 2023;10.1056/NEJMoa2308550. doi:10.1056/NEJMoa2308550

<https://pubmed.ncbi.nlm.nih.gov/37921461/>